Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

No respite for Indian indices
Fri, 16 Aug 01:30 pm

Backed by persistent selling activity the Indian equity markets continued to trade weak during the post noon trading session. All the sectoral indices are witnessing selling pressures, with consumer durables and banking stocks are the leading losers.

BSE-Sensex is down by 545 points and NSE-Nifty is trading down by 173 points. While BSE Mid Cap is trading down by 1.92%, BSE Small Cap index is trading down by 1.55%. The rupee is trading at 61.67 to the US dollar.

Majority of the FMCG stocks are trading in the red with Hindustan Unilever and Marico being among major losers. As per a leading financial daily, Marico has said that it is looking at expanding its presence in sub-segments of value-added hair oils. The company feels that with rising incomes, consumers are increasingly opting for value-added hair oils. Marico has already established a strong franchise in Nihar, Parachute Advanced and Hair & Care brands. As per the company, its value-added hair oils have a 27% share in the Rs 45 bn value-added hair-oil market. The company wants to introduce new products in these established brands and wants to participate in all sub-segments and have a wider portfolio to drive growth. Presently. Marico derives 16% of its revenues from value-added hair oils. Marico stock is currently trading down by 1.4%.

Most of the Indian pharma Stocks are trading in red, with Orchid chemicals and Glenmark pharmaceuticals are among the leading losers. Wockhardt Pharma has declared its June quarter results. Net sales grew marginally by 1.3% YoY for the quarter. This was due to poor performance in most of its business segments. The operating of the margins also witnessed decline of 5% to 31% in 1QFY14. This too impacted the operating profits which declined by 12.8% YoY. Net profits declined by 14.5% on back of overall increase in expenses and poor topline growth

The company also mentioned that its Chikalthana facility has received some 483 observations from USFDA (United states food and drug administration). Though company continues to manufacture drugs from this facility, the company is also working with USFDA to resolve the observations given by the agency. This facility generated approx $230 m of revenues for FY13 (that is approx 25% of FY13 revenues). Company's important product Toprol XL (which contributes approx 13%-14% to company's topline) is also manufactured in this facility. Wockhardt was trading up by 4.5%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "No respite for Indian indices". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.